| Scott J Piper, MD | |
|
1630 42nd St Ne, Suite F, Cedar Rapids, IA 52402-3063 | |
| (319) 261-1379 | |
| (319) 261-1382 |
| Full Name | Scott J Piper |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 1630 42nd St Ne, Cedar Rapids, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194712976 | NPI | - | NPPES |
| 1258434 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 34569 (Iowa) | Primary |
| Entity Name | Piper Family Medicine Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740538974 PECOS PAC ID: 6800049008 Enrollment ID: O20130122000548 |
News Archive
New research led by Queen's University Belfast has found that colorectal cancer costs Europe a staggering €19.1 billion (£16.3 billion) per year. This figure includes direct expenditure as well as indirect costs including premature death and sick leave.
Aspyra, Inc. (AMEX: APY), a provider of clinical and diagnostic information systems for the healthcare industry, today reported its results of operations for the second quarter ended June 30, 2009.
The calcium channel blocker amlodipine decreases the risk of cardiovascular events (such as heart attack or heart-disease related deaths) in patients with coronary artery disease and normal blood pressure, as does the ACE inhibitor enalapril, but to a lesser extent, according to a study in the November 10 issue of JAMA.
Watson Pharmaceuticals, Inc. has confirmed that it has filed two Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration seeking approval to market its guaifenesin extended-release 600mg and 1200mg tablets and its dextromethorphan HBr/guaifenesin extended-release 30mg/600mg and 60mg/1200mg tablets prior to the expiration of patents owned by Reckitt Benckiser Inc.
› Verified 2 days ago
| Entity Name | Amenity Healthcare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932868205 PECOS PAC ID: 2466477484 Enrollment ID: O20220407001687 |
News Archive
New research led by Queen's University Belfast has found that colorectal cancer costs Europe a staggering €19.1 billion (£16.3 billion) per year. This figure includes direct expenditure as well as indirect costs including premature death and sick leave.
Aspyra, Inc. (AMEX: APY), a provider of clinical and diagnostic information systems for the healthcare industry, today reported its results of operations for the second quarter ended June 30, 2009.
The calcium channel blocker amlodipine decreases the risk of cardiovascular events (such as heart attack or heart-disease related deaths) in patients with coronary artery disease and normal blood pressure, as does the ACE inhibitor enalapril, but to a lesser extent, according to a study in the November 10 issue of JAMA.
Watson Pharmaceuticals, Inc. has confirmed that it has filed two Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration seeking approval to market its guaifenesin extended-release 600mg and 1200mg tablets and its dextromethorphan HBr/guaifenesin extended-release 30mg/600mg and 60mg/1200mg tablets prior to the expiration of patents owned by Reckitt Benckiser Inc.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott J Piper, MD 1630 42nd St Ne, Suite F, Cedar Rapids, IA 52402-3063 Ph: (319) 261-1379 | Scott J Piper, MD 1630 42nd St Ne, Suite F, Cedar Rapids, IA 52402-3063 Ph: (319) 261-1379 |
News Archive
New research led by Queen's University Belfast has found that colorectal cancer costs Europe a staggering €19.1 billion (£16.3 billion) per year. This figure includes direct expenditure as well as indirect costs including premature death and sick leave.
Aspyra, Inc. (AMEX: APY), a provider of clinical and diagnostic information systems for the healthcare industry, today reported its results of operations for the second quarter ended June 30, 2009.
The calcium channel blocker amlodipine decreases the risk of cardiovascular events (such as heart attack or heart-disease related deaths) in patients with coronary artery disease and normal blood pressure, as does the ACE inhibitor enalapril, but to a lesser extent, according to a study in the November 10 issue of JAMA.
Watson Pharmaceuticals, Inc. has confirmed that it has filed two Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration seeking approval to market its guaifenesin extended-release 600mg and 1200mg tablets and its dextromethorphan HBr/guaifenesin extended-release 30mg/600mg and 60mg/1200mg tablets prior to the expiration of patents owned by Reckitt Benckiser Inc.
› Verified 2 days ago
Dr. Sameer Bharat Nathoo, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1201 3rd Ave Se, Cedar Rapids, IA 52403 Phone: 319-730-7300 Fax: 319-369-7494 | |
Dr. Gina M Perri, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 275 10th St Se, Cedar Rapids, IA 52403 Phone: 319-364-7730 | |
Donal Kevin Gordon, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1201 3rd Ave Se, Cedar Rapids, IA 52403 Phone: 319-730-7300 | |
Mina Soleimani, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 202 10th St Se, Cedar Rapids, IA 52403 Phone: 319-364-7730 Fax: 877-781-3981 | |
Dr. Keri L Mounce, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 777 76th Avenue Dr Sw, Cedar Rapids, IA 52404 Phone: 319-558-0355 Fax: 319-558-0356 | |
Katherine C Arcenas, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1201 3rd Ave Se, Cedar Rapids, IA 52403 Phone: 319-730-7300 | |
Jennifer Lynn Beck, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 610 8th St Se, Cedar Rapids, IA 52401 Phone: 319-398-6170 Fax: 319-398-6466 |